Women in sub-Saharan Africa continues to be among the hardest hit by HIV. Six of the 10 new HIV infections occur among adult women, mainly by unprotected sex with an infected male. Male condoms are effective in preventing HIV, but women can not always control their use.United States, MTN-001 was performed in Case Western Reserve University in Cleveland, the University of Pittsburgh, University of Alabama at Birmingham and Bronx Lebanon Hospital, Columbia University, New York. In Africa, the study was conducted at Makerere University-Johns Hopkins University Research Collaboration in Kampala, Uganda and Umkomaas and Botha’s Hill site, a subsidiary of clinical research at the Medical Research Council of South Africa in Durban. The three African sites are among the 15 votes is leading.
Quite simply, no one approach will be suitable for all women, said Alexandra Minnis, Ph.D., MPH, an epidemiologist with RTI International in San Francisco and co-author of the study.
Viread and Truvada are registered trademarks of Gilead Sciences, Inc., Foster City, California, USA Both have been evaluated in clinical studies to determine whether they could prevent HIV in people who are HIV-negative, an approach known as oral pre- exposure, or PREP. A recent essay entitled iPrEx found that daily use of Truvada reduces the risk of HIV by 44 % among men who have sex with men.
In the first study to face-to-head comparisons of oral tenofovir gel, tenofovir and – two promising approaches for prevention in women – the researchers found that daily use of a vaginal gel reaches more than 100 times the concentration of the vaginal tissues active drug compared with oral tablets, whereas from the gel, the tablet used daily was associated with a concentration of active drug 20 times higher in the blood.
Surprisingly, people of all demographic groups – regardless of age, sex, education and socioeconomic status – showed a general lack of awareness on how to recognize a stroke, researchers said Arvind Chandratheva Clinical Research Unit in the prevention of ‘ stroke in the department of clinical neurology at the University of Oxford in the United Kingdom.
Tenofovir is a vaginal microbicide gel that contains the same active ingredient as the tablet formulation of oral tenofovir. Microbicides are products designed to prevent or reduce the sexual transmission of HIV when applied topically to the vagina or rectum. In CAPRISA 004, there were 39 % fewer infections among women who used tenofovir gel before and after sex than women who used a placebo gel. The item, women are freezing all day, no matter when they have sex. The Food and Drug Administration said it intends to approve tenofovir gel as a method of HIV prevention for women, according to the results of the vote.
Results MTN-001 will be better understood in the context of voting results, expected in 2013, Dr. This includes understanding that approach – and in what dose – may be optimal for preventing HIV. ITEM – Interventions in the vaginal and oral anti – is the symbol of MTN, a highly effective studies of tenofovir gel, tenofovir and oral Truvada, the inclusion of women in South Africa 5000. The researchers designed MTN-001 and the voice as other studies.
The results of phase II trial, which examined the differences in drug absorption and preferences of women for each diet were 18 reported to the Conference on Retroviruses and Opportunistic Infections . The study, known as MTN-001, did not assess the effectiveness of each approach.
MTN-001 144 women involved, divided equally between the U. and in Uganda and South Africa. All women in the study for each product used daily for six weeks, and the two things together, allowing a direct comparison between the oral tablet and vaginal gel formulations of tenofovir, an antiretroviral drug drugs in common use in the treatment of HIV.
In addition to Drs. Hendrix and Minnis, other authors of the study are Vijayanand Gudda, Ph., of the MRC, South Africa, Sharon Riddler, MD, MPH, University of Pittsburgh, Robert A. Salata, MD, Case Western; Nakabiito Clemens, MBChB, MMED, the MU-JHU, Uganda, Craig Hoesley, MD, UAB, Jessica Justman, MD, Columbia University, Lydia Soto-Torres, MD, MPH, National Institute of Allergy and Infectious Diseases , Division and Barbra Richardson, PhD, Centre of Statistics for the prevention of HIV / AIDS, University of Washington.
Most of the women of the United States has favored the oral tablet in the vaginal gel, while the African women who participated in the study favored the gel and tablets as well.
Many African women said they liked the gel because it increased sexual pleasure, said Craig Hendrix, MD, who led the National Institutes of Health -funded study for Microbicide Trials Network .